China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)
China · Delayed Price · Currency is CNY 17.47
-0.38 (-2.13%)
May 12, 2026, 3:04 PM CST
SHE:300294 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 3.44 | 112.7 | 396.99 | 237.47 | 432.2 | 344.53 |
Depreciation & Amortization | 147.98 | 147.98 | 102.98 | 98.57 | 97.03 | 99.35 |
Other Amortization | 16.76 | 16.76 | 13.98 | 15.39 | 13.74 | 13.63 |
Loss (Gain) From Sale of Assets | -5.1 | -5.1 | 0.61 | -1.3 | -0.07 | 0.87 |
Asset Writedown & Restructuring Costs | 309.6 | 309.6 | 83.8 | 326.72 | 53.65 | 80.57 |
Loss (Gain) From Sale of Investments | -59.98 | -59.98 | -65.58 | -99.75 | -43.84 | -43.11 |
Provision & Write-off of Bad Debts | 21.51 | 21.51 | 8.79 | 2.37 | 2.8 | 0.05 |
Other Operating Activities | -3.84 | -28 | -16.59 | 14.46 | 13.92 | 31.26 |
Change in Accounts Receivable | -471.72 | -471.72 | -211.49 | 40.02 | -11.73 | 799.83 |
Change in Inventory | -12.6 | -12.6 | -120.06 | 107.01 | 1.28 | 11.77 |
Change in Accounts Payable | 102.14 | 102.14 | 116.59 | -92.32 | 56.24 | 4.14 |
Change in Unearned Revenue | 5.88 | 5.88 | -4.01 | -3.57 | -4.13 | -1.46 |
Change in Other Net Operating Assets | - | - | - | - | 3.28 | 11.59 |
Operating Cash Flow | -23.95 | 61.16 | 299.78 | 641.73 | 596.44 | 1,345 |
Operating Cash Flow Growth | - | -79.60% | -53.29% | 7.59% | -55.67% | 87.23% |
Capital Expenditures | -603.38 | -535.31 | -197.79 | -87.5 | -138.41 | -68.12 |
Sale of Property, Plant & Equipment | 3.24 | 3.06 | 1.82 | 3.26 | 0.33 | 4.41 |
Cash Acquisitions | - | - | -1,778 | - | - | - |
Divestitures | 193.79 | 193.79 | 239.61 | 269 | - | - |
Investment in Securities | 152.11 | -397.98 | 975.51 | -248.85 | -500 | -2,505 |
Other Investing Activities | 60.15 | 55.52 | 111.26 | 78.33 | 77.86 | 32.4 |
Investing Cash Flow | -194.09 | -680.91 | -647.53 | 14.25 | -560.22 | -2,536 |
Long-Term Debt Issued | - | 47.04 | - | 22.15 | - | 251.85 |
Long-Term Debt Repaid | - | -5.87 | -76.3 | -24.98 | -3.82 | -563.55 |
Net Debt Issued (Repaid) | 52.4 | 41.17 | -76.3 | -2.83 | -3.82 | -311.7 |
Issuance of Common Stock | - | - | - | - | - | 2,400 |
Common Dividends Paid | -156.68 | -156.4 | -232.41 | -100.85 | -83.19 | -46.03 |
Other Financing Activities | -42.28 | -39.84 | 5.24 | -132.97 | 2 | -9.64 |
Financing Cash Flow | -146.57 | -155.07 | -303.47 | -236.65 | -85.01 | 2,032 |
Foreign Exchange Rate Adjustments | -0.25 | -0.13 | - | - | - | - |
Net Cash Flow | -364.85 | -774.96 | -651.23 | 419.33 | -48.79 | 841.39 |
Free Cash Flow | -627.32 | -474.15 | 101.99 | 554.23 | 458.03 | 1,277 |
Free Cash Flow Growth | - | - | -81.60% | 21.00% | -64.14% | 121.72% |
Free Cash Flow Margin | -34.01% | -23.03% | 5.88% | 20.90% | 16.60% | 48.19% |
Free Cash Flow Per Share | -1.22 | -0.93 | 0.20 | 1.10 | 0.91 | 2.93 |
Cash Income Tax Paid | 193.48 | 183.18 | 167.06 | 250.39 | 227.94 | 192.85 |
Levered Free Cash Flow | -634.96 | -361.32 | 16.4 | 376.4 | 354.85 | 1,141 |
Unlevered Free Cash Flow | -633.9 | -360.6 | 16.82 | 376.68 | 355.24 | 1,148 |
Change in Working Capital | -454.32 | -454.32 | -225.2 | 47.79 | 27.01 | 818.22 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.